NN (NNBR) 10-Q 10 May 19 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2019	May 03, 2019
Document And Entity Information [Abstract]
Entity Registrant Name	NN INC
Entity Central Index Key	0000918541
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-Q
Trading Symbol	NNBR
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding		42,366,961

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
Net sales	$ 213,256	$ 169,148
Cost of sales (exclusive of depreciation and amortization shown separately below)	161,269	126,444
Selling, general and administrative expense	28,125	22,177
Acquisition related costs excluded from selling, general and administrative expense	0	1,776
Depreciation and amortization	23,425	14,281
Restructuring and integration expense	(12)	755
Other operating (income) expense, net	(152)	22
Income from operations	601	3,693
Interest expense	13,801	11,996
Loss on extinguishment of debt and write-off of debt issuance costs	2,699	0
Other (income) expense, net	729	(313)
Loss before (provision) benefit for income taxes and share of net income from joint venture	(16,628)	(7,990)
(Provision) benefit for income taxes	(2,241)	1,176
Share of net income from joint venture	269	831
Net loss	(18,600)	(5,983)
Other comprehensive income (loss):
Change in fair value of interest rate swap, net of tax	(3,856)	0
Foreign currency translation gain	1,262	5,465
Other comprehensive income (loss)	(2,594)	5,465
Comprehensive loss	$ (21,194)	$ (518)
Basic net loss per share
Net loss per share (in dollars per share)	$ (0.44)	$ (0.22)
Weighted average shares outstanding (in shares)	41,972	27,597
Diluted net loss per share
Net loss per share (in dollars per share)	$ (0.44)	$ (0.22)
Weighted average shares outstanding (in shares)	41,972	27,597

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 20,269	$ 17,988
Accounts receivable, net	147,131	133,421
Inventories	128,922	122,615
Income tax receivable	653	946
Other current assets	17,475	21,901
Total current assets	314,450	296,871
Property, plant and equipment, net	352,923	361,028
Finance lease right-of-use assets	12,886
Operating lease right-of-use assets	68,458
Goodwill	440,169	439,452
Intangible assets, net	363,608	376,248
Investment in joint venture	21,087	20,364
Other non-current assets	7,412	7,607
Total assets	1,580,993	1,501,570
Current liabilities:
Accounts payable	74,348	65,694
Accrued salaries, wages and benefits	27,990	24,636
Current maturities of long-term debt	33,444	31,280
Current portion of operating lease liability	7,630	0
Other current liabilities	21,700	23,420
Total current liabilities	165,112	145,030
Deferred tax liabilities	87,993	93,482
Non-current income tax payable	3,875	3,875
Long-term debt, net of current portion	826,274	811,471
Operating lease liability, net of current portion	66,975
Other non-current liabilities	35,855	29,417
Total liabilities	1,186,084	1,083,275
Commitments and contingencies (Note 12)
Common stock - $0.01 par value, authorized 45,000 shares, 42,367 and 42,104 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively	424	421
Additional paid-in capital	512,274	511,545
Retained deficit	(83,570)	(62,046)
Accumulated other comprehensive loss	(34,219)	(31,625)
Total stockholders’ equity	394,909	418,295
Total liabilities and stockholders’ equity	$ 1,580,993	$ 1,501,570

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets - Parenthetical - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	45,000,000	45,000,000
Common stock, shares issued (in shares)	42,367,000	42,104,000
Common stock, shares outstanding (in shares)	42,367,000	42,104,000

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	AOCI Attributable to Parent
Beginning balance (in shares) at Dec. 31, 2017		27,572,000
Beginning balance at Dec. 31, 2017	$ 486,104	$ 275	$ 292,494	$ 211,080	$ (17,745)
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Net loss	(5,983)			(5,983)
Cash dividends declared	(1,955)			(1,955)
Share-based compensation expense (in shares)		87,000
Share-based compensation expense	1,256	$ 1	1,255
Shares issued for option exercises (in shares)		23,000
Shares issued for option exercises	242		242
Restricted shares and performance shares forgiven for taxes and forfeited (in shares)		(16,000)
Restricted shares and performance shares forgiven for taxes and forfeited	(287)		(287)
Change in fair value of interest rate swap, net of tax of $1,104	0
Foreign currency translation gain	5,465				5,465
Ending balance (in shares) at Mar. 31, 2018		27,666,000
Ending balance at Mar. 31, 2018	484,859	$ 276	293,704	203,159	(12,280)
Beginning balance (in shares) at Dec. 31, 2018		42,104,000
Beginning balance at Dec. 31, 2018	418,295	$ 421	511,545	(62,046)	(31,625)
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Net loss	(18,600)			(18,600)
Cash dividends declared	(2,942)			(2,942)
Share-based compensation expense (in shares)		281,000
Share-based compensation expense	$ 873	$ 3	870
Shares issued for option exercises (in shares)	0
Restricted shares and performance shares forgiven for taxes and forfeited (in shares)		(18,000)
Restricted shares and performance shares forgiven for taxes and forfeited	$ (141)		(141)
Change in fair value of interest rate swap, net of tax of $1,104	(3,856)				(3,856)
Foreign currency translation gain	1,262				1,262
Ending balance (in shares) at Mar. 31, 2019		42,367,000
Ending balance at Mar. 31, 2019	$ 394,909	$ 424	$ 512,274	$ (83,570)	$ (34,219)

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Changes in Stockholders' Equity (Parenthetical) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Statement of Stockholders' Equity [Abstract]
Change in fair value interest rate swap, tax	$ 1,104

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities
Net loss	$ (18,600)	$ (5,983)
Adjustments to reconcile net loss to net cash provided by (used by) operating activities:
Depreciation and amortization	23,425	14,281
Amortization of debt issuance costs	1,191	1,088
Loss on extinguishment of debt and write-off of debt issuance costs	2,699	0
Share of net income from joint venture, net of cash dividends received	(269)	(831)
Compensation expense from issuance of share-based awards	873	1,256
Deferred income taxes	(4,373)	0
Other	182	347
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	(13,963)	(9,433)
Inventories	(6,302)	(7,791)
Accounts payable	7,236	(296)
Income taxes receivable and payable, net	248	(613)
Other	4,941	7,001
Net cash used by operating activities	(2,712)	(974)
Cash flows from investing activities
Acquisition of property, plant and equipment	(14,073)	(11,860)
Proceeds from liquidation of short-term investment	8,000	0
Cash paid to acquire businesses, net of cash received	0	(14,676)
Cash paid for earnest money for Paragon Medical acquisition	0	(6,000)
Other	2,394	(282)
Net cash used by investing activities	(3,679)	(32,818)
Cash flows from financing activities
Cash paid for debt issuance or prepayment costs	(738)	0
Dividends paid	(2,947)	(1,931)
Proceeds from long-term debt	19,025	10,000
Repayment of long-term debt	(7,522)	(13,000)
Proceeds from (repayments of) short-term debt, net	1,982	(52)
Other	(924)	(1,278)
Net cash provided by (used by) financing activities	8,876	(6,261)
Effect of exchange rate changes on cash flows	(204)	562
Net change in cash and cash equivalents	2,281	(39,491)
Cash and cash equivalents at beginning of period	17,988	224,446
Cash and cash equivalents at end of period	20,269	184,955
Supplemental schedule of non-cash operating, investing and financing activities
Non-cash additions to property, plant and equipment	$ 4,071	$ 2,992

Interim Financial Statements

Interim Financial Statements	3 Months Ended
	Mar. 31, 2019
Quarterly Financial Information Disclosure [Abstract]
Interim Financial Statements	Interim Financial Statements Nature of Business NN, Inc., is a global diversified industrial company that combines advanced engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision components and assemblies for the medical, aerospace and defense, electrical, automotive, and general industrial markets. As used in this Quarterly Report on Form 10-Q, the terms “NN,” the “Company,” “we,” “our,” or “us” refer to NN, Inc., and its subsidiaries. As of March 31, 2019 , we had 51 facilities in North America, Europe, South America, and China. Basis of Presentation The accompanying condensed consolidated financial statements have not been audited, except that the Condensed Consolidated Balance Sheet as of December 31, 2018 , was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2018 (the “ 2018 Annual Report”), which we filed with the U.S. Securities and Exchange Commission (the “SEC”), on March 18, 2019 . In management’s opinion, the accompanying unaudited condensed consolidated financial statements reflect all adjustments necessary to fairly state our results of operations for the three months ended March 31, 2019 and 2018 ; financial position as of March 31, 2019 , and December 31, 2018 ; and cash flows for the three months ended March 31, 2019 and 2018 , on a basis consistent with our audited consolidated financial statements other than the adoption of new accounting standards, such as the new lease standard (see Note 10 ). These adjustments are of a normal recurring nature and are, in the opinion of management, necessary to state fairly the Company’s financial position and operating results for the interim periods. Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted from the interim financial statements presented in this Quarterly Report on Form 10-Q. These unaudited condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and accompanying notes included in the 2018 Annual Report. The results for the three months ended March 31, 2019 , are not necessarily indicative of results for the year ending December 31, 2019 , or any other future periods. Except for per share data or as otherwise indicated, all U.S. dollar amounts presented in the tables in these Notes to Condensed Consolidated Financial Statements are in thousands. Accounting Standards Recently Adopted Leases. On January 1, 2019 , we adopted Accounting Standards Codification (“ASC”) 842, Leases , which superseded ASC 840, Leases . We adopted ASC 842 utilizing the modified retrospective transition approach, therefore, historical financial information and disclosures do not reflect the new standard and will continue to be presented under the previous lease accounting guidance. Under the modified retrospective transition method, we recognized the cumulative effect of the initial adoption adjustment to the opening balance of retained deficit as of January 1, 2019 . The adoption adjustment to retained deficit was less than $0.1 million . As part of the adoption of ASC 842, we elected the package of practical expedients, the short-term lease exemption, and the practical expedient to not separate lease and non-lease components. We recorded lease-related assets and liabilities to our balance sheet for leases with terms greater than twelve months that were classified as operating leases and not previously recorded on our balance sheet. See Note 10 for the required disclosures related to ASC 842. Derivatives and Hedging . In August 2017 , the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities , (“ASU 2017-12”). ASU 2017-12 provides new rules that expand the hedging strategies that qualify for hedge accounting. The new rules also allow additional time to complete hedge effectiveness testing and allow qualitative assessments subsequent to initial quantitative tests if there is supportable expectation that the hedge will remain highly effective. We adopted the guidance on January 1, 2019 . We have applied the new rules to 2019 hedging activities as disclosed in Note 16 to these condensed consolidated financial statements. The new guidance has no effect on our historical financial statements. Effects of Tax Reform in Other Comprehensive Income. In February 2018 , the FASB issued guidance related to the impacts of the U.S. Tax Cuts and Jobs Act of 2017 (“Tax Act”). Under existing U.S. GAAP, the effects of changes in tax rates and laws on deferred tax balances are recorded as a component of income tax expense in the period in which the law was enacted. When deferred tax balances related to items originally recorded in accumulated other comprehensive income (“AOCI”) are adjusted, certain tax effects become stranded in AOCI. The FASB issued ASU 2018-2, Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, that permits reclassification of certain income tax effects of the Tax Act from AOCI to retained earnings. The guidance also requires certain disclosures about stranded tax effects. The new guidance was effective for us on January 1, 2019 . We adopted the new guidance at the beginning of the period of adoption. The new guidance had no effect on our financial statements. Accounting Standards Not Yet Adopted Fair Value Disclosures. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement, that modifies fair value disclosure requirements. The new guidance could impact us by streamlining disclosures of Level 3 fair value measurements. The modified disclosures are effective for NN beginning in the first quarter of 2020 , with early adoption allowed. ASU 2018-13 changes only disclosures and does not impact our financial condition, results of operations, or cash flows. We are in the process of evaluating the effects of this guidance on our fair value disclosures. Internal-Use Software. In August 2018, the FASB issued ASU 2018-15, Intangibles - Goodwill and Other - Internal-Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (a consensus of the FASB Emerging Issues Task Force), that provides guidance on a customer’s accounting for implementation, set-up, and other upfront costs incurred in a cloud computing arrangement that is hosted by the vendor. Under the new guidance, customers will apply the same criteria for capitalizing implementation costs as they would for an arrangement that has a software license. ASU 2018-15 is effective for us on January 1, 2020 , using either a prospective or retrospective approach and with early adoption permitted. We are in the process of evaluating the effects of this guidance on our financial statements.

Acquisitions

Acquisitions	3 Months Ended
	Mar. 31, 2019
Business Combinations [Abstract]
Acquisitions	Acquisitions Paragon Medical, Inc. On May 7, 2018 , we acquired 100% of the stock of PMG Intermediate Holding Corporation, the parent company of Paragon Medical, Inc. (“Paragon Medical”). For accounting purposes, Paragon Medical meets the definition of a business and has been accounted for as a business combination. Paragon Medical is a medical device manufacturer which focuses on the orthopedic, case and tray, implant, and instrument markets. This acquisition continues our strategic focus to expand our Life Sciences portfolio as well as create a balanced business by diversifying our products and finished device offerings. We have performed an assessment of the opening balance sheet which is subject to completion of our internal review procedures over fair value estimates. Opening balance sheet deferred taxes have been recorded based on estimates made as of the acquisition date as well as information currently available to management. As estimates are refined and additional information is received throughout the measurement period, adjustments to opening deferred taxes may be recorded with an offsetting adjustment to goodwill. Beginning May 7, 2018 , our consolidated results of operations include the results of Paragon Medical. The unaudited pro forma financial results shown in the table below for the three months ended March 31, 2018 , combine the consolidated results of NN and Paragon Medical giving effect to the Paragon Medical acquisition as if it had been completed on January 1, 2017. The unaudited pro forma financial results do not give effect to any of our other acquisitions that occurred after January 1, 2017, and do not include any anticipated synergies or other assumed benefits of the Paragon Medical acquisition. This unaudited pro forma financial information is presented for informational purposes only and is not indicative of future operations or results had the Paragon Medical acquisition been completed as of January 1, 2017. The unaudited pro forma financial results include certain adjustments for debt service costs and additional depreciation and amortization expense based upon the fair value step-up and estimated useful lives of Paragon Medical depreciable fixed assets and definite-life amortizable assets acquired. The provision for income taxes has also been adjusted for all periods, based upon the foregoing adjustments to historical results. Three Months Ended March 31, 2018 Pro forma net sales $ 209,830 Pro forma net loss $ (8,077 ) Basic net loss per share $ (0.29 ) Diluted net loss per share $ (0.29 ) Other Acquisitions Bridgemedica, LLC. On February 22, 2018 , we completed the acquisition of 100% of the assets of Bridgemedica, LLC (“Bridgemedica”) . For accounting purposes, Bridgemedica meets the definition of a business and has been accounted for as a business combination. Bridgemedica is a medical device company that provides concept to supply solutions through design, development engineering, and manufacturing. Operating results of Bridgemedica are reported in our Life Sciences group after the acquisition date. We have finalized the purchase price allocation with no material changes to the initial allocation. Southern California Technical Arts, Inc. On August 9, 2018 , we completed the acquisition of 100% of the capital stock of Southern California Technical Arts, Inc. (“Technical Arts”). For accounting purposes, Technical Arts meets the definition of a business and has been accounted for as a business combination. Technical Arts is an industrial machining company that manufactures tight tolerance metal components and assemblies. The acquisition of Technical Arts expands our presence in the aerospace and defense end market. Operating results of Technical Arts are reported in our Power Solutions group after the acquisition date. We have completed a preliminary purchase price allocation and are in the process of finalizing the fair value of assets acquired and liabilities assumed.

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2019
Segment Reporting [Abstract]
Segment Information	Segment Information We determined our reportable segments under the provisions of U.S. GAAP related to disclosures about segments of an enterprise. Management has concluded that Mobile Solutions, Power Solutions, and Life Sciences each constitutes an operating segment as each engages in business activities for which it earns revenues and incurs expenses for which separate financial information is available, and this is the level at which the Chief Operating Decision Maker (“CODM”) reviews discrete financial information for purposes of allocating resources and assessing performance. Mobile Solutions Mobile Solutions is focused on growth in the general industrial and automotive end markets. We have developed an expertise in manufacturing highly complex, system critical components for fuel systems, engines and transmissions, power steering systems, and electromechanical motors on a high-volume basis. This expertise has been gained through investment in technical capabilities, processes and systems, and skilled program management and product launch capabilities. Power Solutions Power Solutions is focused on growth in the electrical and aerospace and defense end markets. Within this group we combine materials science expertise with advanced engineering and production capabilities to design and manufacture a broad range of high-precision metal and plastic components, assemblies, and finished devices used in applications ranging from power control to flight control and for military devices. We manufacture a variety of products including electrical contacts, connectors, contact assemblies, and precision stampings for the electrical end market and high precision products for the aerospace and defense end markets utilizing our extensive process technologies for optical grade plastics, thermally conductive plastics, titanium, Inconel, magnesium, and electroplating. Life Sciences Life Sciences is focused on growth in the medical end market. Within this group we combine advanced engineering and production capabilities to design and manufacture a broad range of high-precision metal and plastic components, assemblies, and finished devices. We manufacture a variety of components, assemblies, and instruments, such as surgical knives, bioresorbable implants, surgical staples, cases and trays, orthopedic implants and tools, laparoscopic devices, and drug delivery devices for the medical and life sciences end market. Segment Results The following table presents results of operations for each reportable segment. Mobile Solutions Power Solutions Life Sciences Corporate and Consolidations Total Three Months Ended March 31, 2019 Net sales $ 78,075 $ 49,657 $ 86,008 $ (484 ) (a) $ 213,256 Income (loss) from operations $ 4,107 $ 3,824 $ 3,846 $ (11,176 ) $ 601 Interest expense (13,801 ) Other (3,428 ) Loss before provision for income taxes and share of net income from joint venture $ (16,628 ) Three Months Ended March 31, 2018 Net sales $ 89,794 $ 48,682 $ 31,200 $ (528 ) (a) $ 169,148 Income (loss) from operations $ 9,785 $ 5,233 $ 4,204 $ (15,529 ) $ 3,693 Interest expense (11,996 ) Other 313 Loss before benefit for income taxes and share of net income from joint venture $ (7,990 ) _______________________________ (a) Includes elimination of intersegment transactions occurring during the ordinary course of business. Total Assets as of March 31, 2019 December 31, 2018 Mobile Solutions $ 392,100 $ 356,387 Power Solutions 311,771 297,947 Life Sciences 824,891 802,770 Corporate and Consolidations 52,231 44,466 Total $ 1,580,993 $ 1,501,570

Inventories

Inventories	3 Months Ended
	Mar. 31, 2019
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories are comprised of the following amounts: March 31, 2019 December 31, 2018 Raw materials $ 55,286 $ 52,930 Work in process 47,372 42,578 Finished goods 26,264 27,107 Total inventories $ 128,922 $ 122,615

Goodwill

Goodwill	3 Months Ended
	Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill The following table shows changes in the carrying amount of goodwill. Mobile Solutions Power Solutions Life Sciences Total Balance as of December 31, 2018 $ — $ 94,505 $ 344,947 $ 439,452 Currency impacts — 198 519 717 Balance as of March 31, 2019 $ — $ 94,703 $ 345,466 $ 440,169 Based on the closing price of a share of our common stock as of March 31, 2019 , our market capitalization had declined to a level that is less than the net book value of our stockholders’ equity. A prolonged or significant decline in market capitalization could be an indicator of additional goodwill impairment. We will continue to monitor our market capitalization to determine if an indicator of impairment exists in subsequent periods. During 2018 , as a result of our annual goodwill impairment analysis performed during the fourth quarter of 2018 , we recorded an impairment of $109.1 million in our Power Solutions group. After the impairment, Power Solutions reported a goodwill balance of $94.5 million at December 31, 2018 . Given the carrying value of the Power Solutions reporting unit was equal to its fair value at December 31, 2018 as a result of the 2018 goodwill impairment, if actual performance of the Power Solutions reporting unit falls short of expected results, additional material impairment charges may be required. During the first quarter of 2019 , we reassessed the relevant facts and circumstances and concluded there was no impairment during the period. We will continue to monitor and assess Power Solutions during 2019 .

Intangible Assets, Net

Intangible Assets, Net	3 Months Ended
	Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets, Net The following table shows changes in the carrying amount of intangible assets, net. Mobile Solutions Power Solutions Life Sciences Total Balance as of December 31, 2018 $ 35,892 $ 95,991 $ 244,365 $ 376,248 Amortization (885 ) (2,748 ) (9,017 ) (12,650 ) Other 2 — 8 10 Balance as of March 31, 2019 $ 35,009 $ 93,243 $ 235,356 $ 363,608

Investment in Joint Venture

Investment in Joint Venture	3 Months Ended
	Mar. 31, 2019
Equity Method Investments and Joint Ventures [Abstract]
Investment in Joint Venture	Investment in Joint Venture We own a 49% investment in Wuxi Weifu Autocam Precision Machinery Company, Ltd. (the “JV”), a joint venture located in Wuxi, China. The JV is jointly controlled and managed, and we account for it under the equity method. The following table summarizes activity related to our investment in the JV. Balance as of December 31, 2018 $ 20,364 Share of earnings 269 Foreign currency translation gain 454 Balance as of March 31, 2019 $ 21,087 During the fourth quarter of 2018 , as a result of changing market conditions, the fair value of the JV was assessed and we recorded an impairment charge of $16.6 million against our investment in the JV. The fair value assessment was most significantly affected by changes in our assessment of future growth rates. It is reasonably possible that material deviation of future performance from the estimates used in the 2018 valuation could result in further impairment to our investment in the JV in subsequent periods. There was no impairment of our investment in the JV during the three months ended March 31, 2019 . We recognized sales to the JV of less than $0.1 million and $0.1 million during the three months ended March 31, 2019 and 2018 , respectively.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Our effective tax rate was (13.5)% for the three months ended March 31, 2019 , and 14.7% for the three months ended March 31, 2018 . Our 2019 effective tax rate differs from the U.S. federal statutory tax rate of 21% principally due to a discrete tax charge of $6.0 million related to final tax regulations published by the Department of the Treasury and Internal Revenue Service on February 4, 2019 . The 2019 effective tax rate was also impacted by the minimum tax on global intangible low-tax income (“GILTI”) and earnings outside the United States, which are taxed at different rates than the U.S. federal statutory tax rate of 21% . Our 2018 effective tax rate differed from the U.S. federal statutory tax rate of 21% due to permanent differences including GILTI and earnings outside the United States, which were taxed at different rates than the U.S. federal statutory rate of 21% .

Debt

Debt	3 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Debt	Debt Collectively, our credit facility is comprised of a term loan with a face amount of $545.0 million , maturing on October 19, 2022 (the “Senior Secured Term Loan”); a term loan with a face amount of $300.0 million , maturing on April 3, 2021 (the Incremental Term Loan”); and a revolving line of credit with a face amount of $143.0 million , maturing on October 19, 2020 (the “Senior Secured Revolver”). The credit facility is collateralized by all of our assets. The following table presents debt balances as of March 31, 2019 , and December 31, 2018 . March 31, 2019 December 31, 2018 Senior Secured Term Loan $ 530,625 $ 532,063 Incremental Term Loan 276,000 279,000 Senior Secured Revolver 56,184 38,720 International lines of credit and other loans 10,601 9,810 Total principal 873,410 859,593 Less — current maturities of long-term debt 33,444 31,280 Principal, net of current portion 839,966 828,313 Less — unamortized debt issuance costs 13,692 16,842 Long-term debt, net of current portion $ 826,274 $ 811,471 We capitalized interest costs amounting to $0.6 million and $0.2 million in the three months ended March 31, 2019 and 2018 , respectively, related to construction in progress. Senior Secured Term Loan Outstanding borrowings under the Senior Secured Term Loan bear interest at the greater of 0.75% or one-month London Interbank Offered Rate (“LIBOR”) plus an applicable margin of 3.75% . At March 31, 2019 , the Senior Secured Term Loan bore interest at 6.24% . Incremental Term Loan Outstanding borrowings under the Incremental Term Loan bear interest at one-month LIBOR plus an applicable margin of 3.25% . At March 31, 2019 , the Incremental Term Loan bore interest of 5.74% . Senior Secured Revolver Outstanding borrowings under the Senior Secured Revolver bear interest at one-month LIBOR plus an applicable margin of 3.50% . At March 31, 2019 , the Senior Secured Revolver bore interest of 5.99% . We pay an annual commitment fee of 0.50% for unused capacity under the Senior Secured Revolver on a quarterly basis. Total available capacity under the Senior Secured Revolver was $125.0 million as of March 31, 2019 . Our credit facility is subject to certain financial covenants based on a consolidated net leverage ratio, as defined in the credit facility agreement. The financial covenants are effective when we have outstanding borrowings under our Senior Secured Revolver on the last day of any fiscal quarter, become more restrictive over time, and are dependent upon our operational and financial performance. If our operational or financial performance is below our expectations, we may be required to take actions to reduce expenditures and decrease our net indebtedness to maintain compliance in future periods. We had $56.2 million outstanding under the Senior Secured Revolver at March 31, 2019 , and we were in compliance with all covenants under our credit facility. On March 15, 2019 , we amended our existing credit facility (the “March 2019 amendment”) to amend the defined terms within the credit facility. We paid $0.8 million of debt issuance costs related to the March 2019 amendment which was recorded as a direct reduction to the carrying amount of the associated long-term debt. We also wrote-off $2.7 million of unamortized debt issuance costs related to the modification of the credit facility. Derivative Instruments and Hedging Activities In February 2019, we entered into a $700.0 million amortizing notional amount fixed-rate interest rate swap agreement to manage the interest rate risk associated with our long-term variable-rate debt until 2022. The fixed-rate interest rate swap agreement calls for us to receive interest monthly at a variable rate equal to one-month LIBOR and to pay interest monthly at a fixed rate of 2.4575% . Refer to Note 16 for further discussion of the interest rate swap agreement.

Leases

Leases	3 Months Ended
	Mar. 31, 2019
Leases [Abstract]
Leases	Leases We adopted ASC 842 on January 1, 2019 , and elected the modified retrospective approach in which the new standard is applied to all leases existing at the date of adoption through a cumulative-effect adjustment of less than $0.1 million to retained deficit. Consequently, financial information is not updated, and the disclosures required under the new standard are not provided for periods prior to January 1, 2019 . As part of the adoption, we elected the package of practical expedients, the short-term lease exemption, and the practical expedient to not separate lease and non-lease components permitted within ASC 842. Accordingly, we accounted for our existing operating leases as operating leases under the new standard, without reassessing (a) whether the contracts contain a lease under ASC 842, (b) whether classification of the operating leases would be different in accordance with ASC 842, or (c) whether any unamortized initial direct costs would have met the definition of initial direct costs in ASC 842 at lease commencement. We determine whether an arrangement is a lease at inception. Right-of-use (“ROU”) lease assets represent our right to use an underlying asset for the lease term, and lease obligations represent our obligation to make lease payments arising from the lease. ROU lease assets and obligations are recognized at the lease commencement date based on the present value of lease payments over the lease term. When the implicit rate is not readily determinable, we use the estimated incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Amortization of ROU lease assets is recognized in expense on a straight-line basis over the lease term. Short-term leases are leases having a term of twelve months or less. We recognize short-term leases on a straight-line basis and do not record a related lease asset or liability for such leases. Finance lease ROU assets consist of equipment used in the manufacturing process with terms between thirteen months and five years . Operating lease ROU assets consist of the following: • Equipment used in the manufacturing process as well as office equipment with terms between thirteen months and five years . • Manufacturing plants and office facilities with terms between thirteen months and 25 years . The following table presents components of lease expense for the three months ended March 31, 2019 : Financial Statement Line Item Three Months Ended March 31, 2019 Lease cost: Finance lease cost Amortization of right-of-use assets Depreciation and amortization $ 322 Interest expense Interest expense 53 Operating lease cost Cost of sales and selling, general and administrative expense 3,434 Short-term lease cost (1) Cost of sales and selling, general and administrative expense 107 Total lease cost $ 3,916 _______________________________ (1) Excludes expenses related to leases with a lease term of one month or less. The following table presents the lease-related assets and liabilities recorded on the balance sheet as of March 31, 2019 : Financial Statement Line Item March 31, 2019 Lease assets and liabilities: Assets Operating lease assets Operating lease right-of-use assets $ 68,458 Finance lease asset Finance lease right-of-use assets 12,886 Total lease assets $ 81,344 Liabilities Current liabilities Operating lease liabilities Current portion of operating lease liability $ 7,630 Finance lease liabilities Other current liabilities 2,401 Non-current liabilities Operating lease liabilities Operating lease liability, net of current portion 66,975 Finance lease liabilities Other non-current liabilities 6,150 Total lease liabilities $ 83,156 The following table contains supplemental information related to leases for the three months ended March 31, 2019 : Supplemental Cash Flows Information Three Months Ended March 31, 2019 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from finance leases $ 53 Operating cash flows from operating leases 5,288 Financing cash flows from finance leases 792 Right-of-use assets obtained in exchange for new operating lease liabilities $ 2,836 As of March 31, 2019 , the weighted average remaining lease term and weighted-average discount rate for finance and operating leases was as follows: Weighted-Average Remaining Lease Term (years) Weighted-Average Discount Rate Finance leases 4.1 2.4 % Operating leases 10.5 8.5 % The future minimum lease obligations with noncancelable terms in excess of twelve months as of March 31, 2019 , is as follows: Operating Leases Finance Leases 2019 (1) $ 10,104 $ 2,190 2020 11,979 2,033 2021 11,118 2,020 2022 10,812 1,853 2023 9,264 962 Thereafter 59,946 17 Total future minimum lease payments 113,223 9,075 Less: imputed interest 38,618 524 Total lease liabilities $ 74,605 $ 8,551 (1) For the period from April 1, 2019 to December 31, 2019 . As of March 31, 2019 , we have an additional operating lease commitment that has not yet commenced that would require us to pay a total of approximately $21.9 million base rent payments over the lease term of 15 years . This lease is expected to commence during the fourth quarter of 2019 . The following table summarizes the future minimum lease payments under operating leases with initial or non-cancelable lease terms in excess of one year prior to adoption of ASC 842 as reported in our Annual Report on Form 10-K for the year ended December 31, 2018 . Year Ending December 31, 2019 $ 13,337 2020 11,515 2021 10,557 2022 10,293 2023 8,752 Thereafter 53,945 Total minimum payments $ 108,399 During the three months ended March 31, 2018, we recognized rent expense of $2.1 million .
Leases	Leases We adopted ASC 842 on January 1, 2019 , and elected the modified retrospective approach in which the new standard is applied to all leases existing at the date of adoption through a cumulative-effect adjustment of less than $0.1 million to retained deficit. Consequently, financial information is not updated, and the disclosures required under the new standard are not provided for periods prior to January 1, 2019 . As part of the adoption, we elected the package of practical expedients, the short-term lease exemption, and the practical expedient to not separate lease and non-lease components permitted within ASC 842. Accordingly, we accounted for our existing operating leases as operating leases under the new standard, without reassessing (a) whether the contracts contain a lease under ASC 842, (b) whether classification of the operating leases would be different in accordance with ASC 842, or (c) whether any unamortized initial direct costs would have met the definition of initial direct costs in ASC 842 at lease commencement. We determine whether an arrangement is a lease at inception. Right-of-use (“ROU”) lease assets represent our right to use an underlying asset for the lease term, and lease obligations represent our obligation to make lease payments arising from the lease. ROU lease assets and obligations are recognized at the lease commencement date based on the present value of lease payments over the lease term. When the implicit rate is not readily determinable, we use the estimated incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Amortization of ROU lease assets is recognized in expense on a straight-line basis over the lease term. Short-term leases are leases having a term of twelve months or less. We recognize short-term leases on a straight-line basis and do not record a related lease asset or liability for such leases. Finance lease ROU assets consist of equipment used in the manufacturing process with terms between thirteen months and five years . Operating lease ROU assets consist of the following: • Equipment used in the manufacturing process as well as office equipment with terms between thirteen months and five years . • Manufacturing plants and office facilities with terms between thirteen months and 25 years . The following table presents components of lease expense for the three months ended March 31, 2019 : Financial Statement Line Item Three Months Ended March 31, 2019 Lease cost: Finance lease cost Amortization of right-of-use assets Depreciation and amortization $ 322 Interest expense Interest expense 53 Operating lease cost Cost of sales and selling, general and administrative expense 3,434 Short-term lease cost (1) Cost of sales and selling, general and administrative expense 107 Total lease cost $ 3,916 _______________________________ (1) Excludes expenses related to leases with a lease term of one month or less. The following table presents the lease-related assets and liabilities recorded on the balance sheet as of March 31, 2019 : Financial Statement Line Item March 31, 2019 Lease assets and liabilities: Assets Operating lease assets Operating lease right-of-use assets $ 68,458 Finance lease asset Finance lease right-of-use assets 12,886 Total lease assets $ 81,344 Liabilities Current liabilities Operating lease liabilities Current portion of operating lease liability $ 7,630 Finance lease liabilities Other current liabilities 2,401 Non-current liabilities Operating lease liabilities Operating lease liability, net of current portion 66,975 Finance lease liabilities Other non-current liabilities 6,150 Total lease liabilities $ 83,156 The following table contains supplemental information related to leases for the three months ended March 31, 2019 : Supplemental Cash Flows Information Three Months Ended March 31, 2019 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from finance leases $ 53 Operating cash flows from operating leases 5,288 Financing cash flows from finance leases 792 Right-of-use assets obtained in exchange for new operating lease liabilities $ 2,836 As of March 31, 2019 , the weighted average remaining lease term and weighted-average discount rate for finance and operating leases was as follows: Weighted-Average Remaining Lease Term (years) Weighted-Average Discount Rate Finance leases 4.1 2.4 % Operating leases 10.5 8.5 % The future minimum lease obligations with noncancelable terms in excess of twelve months as of March 31, 2019 , is as follows: Operating Leases Finance Leases 2019 (1) $ 10,104 $ 2,190 2020 11,979 2,033 2021 11,118 2,020 2022 10,812 1,853 2023 9,264 962 Thereafter 59,946 17 Total future minimum lease payments 113,223 9,075 Less: imputed interest 38,618 524 Total lease liabilities $ 74,605 $ 8,551 (1) For the period from April 1, 2019 to December 31, 2019 . As of March 31, 2019 , we have an additional operating lease commitment that has not yet commenced that would require us to pay a total of approximately $21.9 million base rent payments over the lease term of 15 years . This lease is expected to commence during the fourth quarter of 2019 . The following table summarizes the future minimum lease payments under operating leases with initial or non-cancelable lease terms in excess of one year prior to adoption of ASC 842 as reported in our Annual Report on Form 10-K for the year ended December 31, 2018 . Year Ending December 31, 2019 $ 13,337 2020 11,515 2021 10,557 2022 10,293 2023 8,752 Thereafter 53,945 Total minimum payments $ 108,399 During the three months ended March 31, 2018, we recognized rent expense of $2.1 million .

Restructuring and Integration

Restructuring and Integration	3 Months Ended
	Mar. 31, 2019
Restructuring and Related Activities [Abstract]
Restructuring and Integration	Restructuring and Integration The following table summarizes restructuring and integration charges incurred for the three months ended March 31, 2019 and 2018 . Three Months Ended March 31, 2019 Mobile Power Life Corporate and Total Severance and other employee costs $ — $ — $ — $ — $ — Site closure and other associated costs (12 ) — — — (12 ) Total $ (12 ) $ — $ — $ — $ (12 ) Three Months Ended March 31, 2018 Mobile Power Life Corporate and Total Severance and other employee costs $ — $ — $ — $ 728 $ 728 Site closure and other associated costs 27 — — — 27 Total $ 27 $ — $ — $ 728 $ 755 The following table summarizes restructuring and integration reserve activity for the three months ended March 31, 2019 . Reserve Charges Non-cash Adjustments Cash Reductions Reserve Severance and other employee costs $ 1,122 $ — $ — $ (274 ) $ 848 Site closure and other associated costs 24 (12 ) — (12 ) — Total $ 1,146 $ (12 ) $ — $ (286 ) $ 848 The amount accrued for restructuring and integration costs represents what we expect to pay over the next 1.9 years. We expect to pay $0.5 million within the next twelve months.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Brazil ICMS Tax Matter Prior to the acquisition of Autocam Corporation in 2014 (“Autocam”), Autocam’s Brazilian subsidiary (“Autocam Brazil”) received notification from the Brazilian tax authority regarding ICMS (state value added tax or “VAT”) tax credits claimed on intermediary materials (e.g., tooling and perishable items) used in the manufacturing process. The Brazilian tax authority notification disallowed state ICMS tax credits claimed on intermediary materials based on the argument that these items are not intrinsically related to the manufacturing processes. Autocam Brazil filed an administrative defense with the Brazilian tax authority arguing, among other matters, that it should qualify for an ICMS tax credit, contending that the intermediary materials are directly related to the manufacturing process. We believe that we have substantial legal and factual defenses, and we plan to defend our interests in this matter vigorously. The matter encompasses several lawsuits filed with the Brazilian courts requesting declaratory actions that no tax is due or seeking a stay of execution on the collection of the tax. In 2018, we obtained a favorable decision in one of the declaratory actions for which the period for appeal has expired. We have filed actions in each court requesting dismissal of the matter based on the earlier court action. Although we anticipate a favorable resolution to all matters, we can provide no assurances that we will be successful in achieving dismissal of all pending cases. While we believe a loss is not probable, we estimate the range of possible losses related to this assessment is from $0 to $6.0 million . No amount was accrued at March 31, 2019 , for this matter. We are entitled to indemnification from the former shareholders of Autocam, subject to the limitations and procedures set forth in the agreement and plan of merger relating to the Autocam acquisition. Management believes the indemnification would include amounts owed for the tax, interest, and penalties related to this matter. All Other Legal Matters All other legal proceedings are of an ordinary and routine nature and are incidental to our operations. Management believes that such proceedings should not, individually or in the aggregate, have a material adverse effect on our business, financial condition, results of operations, or cash flows. In making that determination, we analyze the facts and circumstances of each case at least quarterly in consultation with our attorneys and determine a range of reasonably possible outcomes.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	3 Months Ended
	Mar. 31, 2019
Revenue from Contract with Customer [Abstract]
Revenue from Contracts with Customers	Revenue from Contracts with Customers Revenue is recognized when control of the good or service is transferred to the customer either at a point in time or, in limited circumstances, as our services are rendered over time. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or services. Sales, value add, and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. Incidental items that are immaterial in the context of the contract are recognized as expense. The following tables summarize sales to external customers by major source. Three Months Ended March 31, 2019 Mobile Power Life Intersegment Total United States $ 44,457 $ 41,115 $ 68,343 $ (484 ) $ 153,431 China 9,153 1,838 1,692 — 12,683 Mexico 5,378 2,709 127 — 8,214 Brazil 8,382 69 — — 8,451 Germany 1,406 16 8,885 — 10,307 Switzerland 1,359 16 3,265 — 4,640 Poland 1,913 4 6 — 1,923 Italy 1,856 63 421 — 2,340 Czech Republic 1,509 188 — — 1,697 France 44 — 1,225 — 1,269 Africa — 1,156 — — 1,156 Other 2,618 2,483 2,044 — 7,145 Total net sales $ 78,075 $ 49,657 $ 86,008 $ (484 ) $ 213,256 Three Months Ended March 31, 2018 Mobile Solutions Power Solutions Life Sciences Intersegment Sales Eliminations Total United States $ 49,655 $ 40,128 $ 30,553 $ (528 ) $ 119,808 China 11,581 1,485 126 — 13,192 Mexico 7,236 3,197 172 — 10,605 Brazil 9,885 50 — — 9,935 Poland 2,052 14 — — 2,066 Czech Republic 1,810 — — — 1,810 Italy 1,577 98 — — 1,675 Germany 1,534 7 1 — 1,542 Switzerland 1,406 — — — 1,406 Netherlands — 974 — — 974 Other 3,058 2,729 348 — 6,135 Total net sales $ 89,794 $ 48,682 $ 31,200 $ (528 ) $ 169,148 Deferred Revenue The following table provides information about contract liabilities from contracts with customers. Deferred Revenue Balance at January 1, 2019 $ 2,974 Balance at March 31, 2019 $ 2,890 Revenue recognized during the three months ended March 31, 2019 , from amounts included in deferred revenue at the beginning of the period for performance obligations satisfied or partially satisfied during the period, was approximately $0.6 million . Transaction Price Allocated to Future Performance Obligations We are required to disclose the aggregate amount of transaction price that is allocated to performance obligations that have not yet been satisfied as of March 31, 2019 , unless our contracts meet one of the practical expedients. Our contracts met the following practical expedient provided by the guidance: • The performance obligation is part of a contract that has an original expected duration of one year or less. Sales Concentration During the three months ended March 31, 2019 , we recognized sales from a single customer of $23.3 million , or 10.9% of consolidated net sales. Revenues from this customer are in our Life Sciences and Power Solutions groups. No customers represented more than 10% of our net sales during the three months ended March 31, 2018 .

Shared-Based Compensation

Shared-Based Compensation	3 Months Ended
	Mar. 31, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Shared-Based Compensation	Shared-Based Compensation The following table lists the components of share-based compensation expense by type of award. Three Months Ended 2019 2018 Stock options $ 192 $ 205 Restricted stock 459 460 Performance share units 222 591 Share-based compensation expense $ 873 $ 1,256 Stock Options During the three months ended March 31, 2019 , we granted options to purchase 210,400 shares to certain key employees. The weighted average grant date fair value of the options granted during the three months ended March 31, 2019 , was $2.77 per share. The fair value of our options cannot be determined by market value because they are not traded in an open market. Accordingly, we utilized the Black Scholes financial pricing model to estimate the fair value. The following table shows the weighted average assumptions relevant to determining the fair value of stock options granted in 2019 . 2019 Expected term 6 years Risk free interest rate 2.47 % Dividend yield 3.53 % Expected volatility 49.53 % Expected forfeiture rate 4.00 % The expected term is derived from using the simplified method of determining stock option terms as described under the Staff Accounting Bulletin Topic 14, Share-based payment . The simplified method was used because sufficient historical stock option exercise experience was not available, primarily due to the transformation of the management structure over the past several years. The average risk-free interest rate is derived from United States Department of Treasury published interest rates of daily yield curves for the same time period as the expected term. The expected dividend yield is derived by a mathematical formula which uses the expected annual dividends over the expected term divided by the fair market value of our common stock at the grant date. The expected volatility rate is derived from our actual common stock historical volatility over the same time period as the expected term. The volatility rate is derived by mathematical formula utilizing daily closing price data. The forfeiture rate is determined from examining the historical pre-vesting forfeiture patterns of past option issuances to key employees. While the forfeiture rate is not an input of the Black Scholes model for determining the fair value of the options, it is an important determinant of stock option compensation expense to be recorded. The following table summarizes stock option activity for the three months ended March 31, 2019 . Number of Options (in thousands) Weighted- Average Exercise Price (per share) Weighted- Average Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at January 1, 2019 771 $ 15.17 Granted 210 7.93 Exercised — $ — Forfeited or expired (3 ) 24.41 Outstanding at March 31, 2019 978 $ 13.58 6.3 $ — (1) Exercisable at March 31, 2019 701 $ 14.27 5.0 $ — (1) _______________________________ (1) The aggregate intrinsic value is the sum of intrinsic values for each exercisable individual option grant. The intrinsic value is the amount by which the closing market price of our stock at March 31, 2019 , was greater than the exercise price of any individual option grant. Restricted Stock During the three months ended March 31, 2019 , we granted 281,065 restricted stock awards to non-executive directors, officers and certain other key employees. The shares of restricted stock granted during the three months ended March 31, 2019 , vest pro-rata over three years for officers and certain other key employees and over one year for non-executive directors. We determined the fair value of the shares awarded by using the closing price of our common stock as of the date of grant. The weighted average grant date value of restricted stock granted in the three months ended March 31, 2019 , was $7.93 per share. Total grant-date fair value of restricted stock that vested in the three months ended March 31, 2019 , was $1.5 million . The following table summarizes the status of unvested restricted stock awards as of March 31, 2019 , and changes during the three months then ended. Nonvested Restricted Shares (in thousands) Weighted Average Grant-Date Fair Value (per share) Nonvested at January 1, 2019 146 $ 22.07 Granted 281 $ 7.93 Vested (70 ) $ 20.92 Forfeited (18 ) $ 18.98 Nonvested at March 31, 2019 339 $ 10.74 Performance Share Units Performance Share Units (“PSUs”) are a form of long-term incentive compensation awarded to executive officers and certain other key employees designed to directly align the interests of employees to the interests of our stockholders, and to create long-term stockholder value. PSU awards granted in 2019 were made pursuant to the NN, Inc. 2016 Omnibus Incentive Plan and a Performance Share Unit Agreement (the “2016 Omnibus Agreement”). Some PSUs are based on total shareholder return (“TSR Awards”), and other PSUs are based on return on invested capital (“ROIC Awards”). The TSR Awards vest, if at all, upon our achieving a specified relative total shareholder return, which will be measured against the total shareholder return of the S&P SmallCap 600 Index during specified performance periods as defined in the 2016 Omnibus Agreement. The ROIC Awards vest, if at all, upon our achieving a specified average return on invested capital during the performance periods. Each performance period generally begins on January 1 of the year of grant and ends 36 months later on December 31. We recognize compensation expense over the performance period in which the performance and market conditions are measured. If the PSUs do not vest at the end of the performance periods, then the PSUs will expire automatically. Upon vesting, the PSUs will be settled by the issuance of shares of our common stock, subject to the executive officer’s continued employment. The actual number of shares of common stock to be issued to each award recipient at the end of the performance periods will be interpolated between a threshold and maximum payout amount based on actual performance results. No dividends will be paid on outstanding PSUs during the performance period; however, dividend equivalents will be paid based on the number of shares of common stock that are ultimately earned at the end of the performance periods. With respect to the TSR Awards, a participant will earn 50% of the target number of PSUs for “Threshold Performance,” 100% of the target number of PSUs for “Target Performance,” and 150% of the target number of PSUs for “Maximum Performance.” With respect to the ROIC Awards, a participant will earn 35% of the target number of PSUs for “Threshold Performance,” 100% of the target number of PSUs for “Target Performance,” and 150% of the target number of PSUs for “Maximum Performance. For performance levels falling between the values shown below, the percentages will be determined by interpolation. The following table presents the goals with respect to TSR Awards and ROIC Awards granted in 2019 . TSR Awards: Threshold Performance Target Performance Maximum Performance 2019 grants 35th Percentile 50th Percentile 75th Percentile ROIC Awards: Threshold Performance Target Performance Maximum Performance 2019 grants (1) 4.7 % 5.8 % 7.0 % (1) For the ROIC Awards granted in 2019, the denominator of the calculation is different than in prior years, and therefore the target percentages are not comparable to historical target percentages. We estimate the grant date fair value of TSR Awards using the Monte Carlo simulation model, as the total shareholder return metric is considered a market condition under ASC Topic 718, Compensation – stock compensation . The grant date fair value of ROIC Awards is based on the closing price of a share of our common stock on the date of grant. The following table presents the number of awards granted and the grant date fair value of each award in the period presented. TSR Awards ROIC Awards Award Year Shares (in thousands) Grant Date Fair Value (per share) Shares (in thousands) Grant Date Fair Value (per share) 2019 136 $ 9.28 174 $ 7.93 We recognize expense for ROIC Awards based on the probable outcome of the associated performance condition. We generally recognize an expense for ROIC Awards based on the Target Performance threshold of 100% because, at the date of grant, the Target Performance is the probable level of performance achievement. The following table summarizes the status of unvested PSUs as of March 31, 2019 , and changes during the three months then ended. Nonvested TSR Awards Nonvested ROIC Awards Shares (in thousands) Weighted Average Grant-Date Fair Value (per share) Shares (in thousands) Weighted Average Grant-Date Fair Value (per share) Nonvested at January 1, 2019 94 $ 26.84 100 $ 24.39 Granted 136 $ 9.28 174 $ 7.93 Forfeited — $ — — $ — Nonvested at March 31, 2019 230 $ 16.47 274 $ 13.93

Net Income (Loss) Per Share

Net Income (Loss) Per Share	3 Months Ended
	Mar. 31, 2019
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	Net Income (Loss) Per Share Three Months Ended 2019 2018 Numerator: Net loss $ (18,600 ) $ (5,983 ) Denominator: Weighted average shares outstanding 41,972 27,597 Effect of dilutive stock options — — Diluted shares outstanding 41,972 27,597 Per common share net loss: Basic net loss per share $ (0.44 ) $ (0.22 ) Diluted net loss per share $ (0.44 ) $ (0.22 ) Cash dividends declared per share $ 0.07 $ 0.07 The calculation of diluted net loss per share for the three months ended March 31, 2019 and 2018 , excludes 0.7 million and 0.5 million potentially dilutive stock options, which had the effect of being anti-dilutive. Given the net loss for the three months ended March 31, 2019 and 2018 , all options are considered anti-dilutive and were excluded from the calculation of diluted net loss per share.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Fair value is an exit price representing the expected amount that an entity would receive to sell an asset or pay to transfer a liability in an orderly transaction with market participants at the measurement date. We followed consistent methods and assumptions to estimate fair values as more fully described in the 2018 Annual Report. Our financial instruments that are subject to fair value disclosure consist of cash and cash equivalents, accounts receivable, accounts payable, derivatives, and long-term debt. As of March 31, 2019 , the carrying values of these financial instruments approximated fair value. The fair value of floating-rate debt approximates the carrying amount because the interest rates paid are based on short-term maturities. As of March 31, 2019 , we had $10.6 million fixed-rate debt outstanding included in the “International lines of credit and other loans” line item within Note 9 to these Notes to Condensed Consolidated Financial Statements . These fair values represent Level 2 under the three-tier hierarchy described above. Due to the nature of these loans, fair value approximates book value. Recurring Fair Value Measurements Fair value principles prioritize valuation inputs across three broad levels. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on the assumptions used to measure assets and liabilities at fair value. An asset or liability’s classification within the various levels is determined based on the lowest level input that is significant to the fair value measurement. We manage our exposure to fluctuations in interest rates using a mix of fixed and variable rate debt. On February 8, 2019, we entered into a $700.0 million fixed-rate interest rate swap agreement that changed the LIBOR-based portion of the interest rate on a portion of our variable rate debt to a fixed rate of 2.4575% (the “interest rate swap”). The term of the interest rate swap is from the effective date of February 12, 2019 , through the termination date of October 19, 2022 (the “interest rate swap term”). The interest rate swap effectively mitigates our exposures to the risks and variability of changes in LIBOR. The notional amount of the interest rate swap will decrease over the interest rate swap term as follows: Notional Amount February 12, 2019 - December 30, 2020 $ 700,000 December 31, 2020 - December 30, 2021 466,667 December 31, 2021 - October 19, 2022 233,333 The objective of the interest rate swap is to eliminate the variability of cash flows in interest payments on the first $700.0 million of variable rate debt attributable to changes in benchmark one-month LIBOR interest rates. The hedged risk is the interest rate risk exposure to changes in interest payments, attributable to changes in benchmark one-month LIBOR interest rates over the interest rate swap term. If one-month LIBOR is greater than the minimum percentage under the Senior Secured Term Loan, the changes in cash flows of the interest rate swap are expected to exactly offset changes in cash flows of the variable rate debt. The interest rate swap is designated as a cash flow hedge. As of March 31, 2019 , we reported $3.9 million loss , net of tax, in accumulated other comprehensive income related to the interest rate swap. The following shows the liabilities measured at fair value on a recurring basis for the interest rate swap as of March 31, 2019 . Fair Value Measurements as of March 31, 2019 Description Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Derivative liability - other current liabilities $ — $ 543 $ — Derivative liability - other non-current liabilities — 4,417 — Total $ — $ 4,960 $ — The inputs for determining fair value of the interest rate swap are classified as Level 2 inputs. Level 2 fair value is based on estimates using standard pricing models. These standard pricing models use inputs which are derived from or corroborated by observable market data such as interest rate yield curves, index forward curves, discount curves, and volatility surfaces. Counterparty to this derivative contracts is a highly rated financial institution which we believe carries only a minimal risk of nonperformance. As of December 31, 2018 , we had no interest rate swap agreements outstanding.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	Subsequent Event Tennessee Shared Service Center Closure On April 18, 2019, we announced the closure of our shared service center in Johnson City, Tennessee, effective at the end of June 2019. Closure of the Tennessee shared service center aligns with our focus on operating excellence and efficiency and is not expected to have a material impact on our financial statements.

Interim Financial Statements (P

Interim Financial Statements (Policies)	3 Months Ended
	Mar. 31, 2019
Quarterly Financial Information Disclosure [Abstract]
Nature of Business	Nature of Business NN, Inc., is a global diversified industrial company that combines advanced engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision components and assemblies for the medical, aerospace and defense, electrical, automotive, and general industrial markets. As used in this Quarterly Report on Form 10-Q, the terms “NN,” the “Company,” “we,” “our,” or “us” refer to NN, Inc., and its subsidiaries. As of March 31, 2019 , we had 51 facilities in North America, Europe, South America, and China.
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements have not been audited, except that the Condensed Consolidated Balance Sheet as of December 31, 2018 , was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2018 (the “ 2018 Annual Report”), which we filed with the U.S. Securities and Exchange Commission (the “SEC”), on March 18, 2019 . In management’s opinion, the accompanying unaudited condensed consolidated financial statements reflect all adjustments necessary to fairly state our results of operations for the three months ended March 31, 2019 and 2018 ; financial position as of March 31, 2019 , and December 31, 2018 ; and cash flows for the three months ended March 31, 2019 and 2018 , on a basis consistent with our audited consolidated financial statements other than the adoption of new accounting standards, such as the new lease standard (see Note 10 ). These adjustments are of a normal recurring nature and are, in the opinion of management, necessary to state fairly the Company’s financial position and operating results for the interim periods. Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted from the interim financial statements presented in this Quarterly Report on Form 10-Q. These unaudited condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and accompanying notes included in the 2018 Annual Report. The results for the three months ended March 31, 2019 , are not necessarily indicative of results for the year ending December 31, 2019 , or any other future periods. Except for per share data or as otherwise indicated, all U.S. dollar amounts presented in the tables in these Notes to Condensed Consolidated Financial Statements are in thousands.
Accounting Standards	Accounting Standards Recently Adopted Leases. On January 1, 2019 , we adopted Accounting Standards Codification (“ASC”) 842, Leases , which superseded ASC 840, Leases . We adopted ASC 842 utilizing the modified retrospective transition approach, therefore, historical financial information and disclosures do not reflect the new standard and will continue to be presented under the previous lease accounting guidance. Under the modified retrospective transition method, we recognized the cumulative effect of the initial adoption adjustment to the opening balance of retained deficit as of January 1, 2019 . The adoption adjustment to retained deficit was less than $0.1 million . As part of the adoption of ASC 842, we elected the package of practical expedients, the short-term lease exemption, and the practical expedient to not separate lease and non-lease components. We recorded lease-related assets and liabilities to our balance sheet for leases with terms greater than twelve months that were classified as operating leases and not previously recorded on our balance sheet. See Note 10 for the required disclosures related to ASC 842. Derivatives and Hedging . In August 2017 , the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities , (“ASU 2017-12”). ASU 2017-12 provides new rules that expand the hedging strategies that qualify for hedge accounting. The new rules also allow additional time to complete hedge effectiveness testing and allow qualitative assessments subsequent to initial quantitative tests if there is supportable expectation that the hedge will remain highly effective. We adopted the guidance on January 1, 2019 . We have applied the new rules to 2019 hedging activities as disclosed in Note 16 to these condensed consolidated financial statements. The new guidance has no effect on our historical financial statements. Effects of Tax Reform in Other Comprehensive Income. In February 2018 , the FASB issued guidance related to the impacts of the U.S. Tax Cuts and Jobs Act of 2017 (“Tax Act”). Under existing U.S. GAAP, the effects of changes in tax rates and laws on deferred tax balances are recorded as a component of income tax expense in the period in which the law was enacted. When deferred tax balances related to items originally recorded in accumulated other comprehensive income (“AOCI”) are adjusted, certain tax effects become stranded in AOCI. The FASB issued ASU 2018-2, Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, that permits reclassification of certain income tax effects of the Tax Act from AOCI to retained earnings. The guidance also requires certain disclosures about stranded tax effects. The new guidance was effective for us on January 1, 2019 . We adopted the new guidance at the beginning of the period of adoption. The new guidance had no effect on our financial statements. Accounting Standards Not Yet Adopted Fair Value Disclosures. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement, that modifies fair value disclosure requirements. The new guidance could impact us by streamlining disclosures of Level 3 fair value measurements. The modified disclosures are effective for NN beginning in the first quarter of 2020 , with early adoption allowed. ASU 2018-13 changes only disclosures and does not impact our financial condition, results of operations, or cash flows. We are in the process of evaluating the effects of this guidance on our fair value disclosures. Internal-Use Software. In August 2018, the FASB issued ASU 2018-15, Intangibles - Goodwill and Other - Internal-Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (a consensus of the FASB Emerging Issues Task Force), that provides guidance on a customer’s accounting for implementation, set-up, and other upfront costs incurred in a cloud computing arrangement that is hosted by the vendor. Under the new guidance, customers will apply the same criteria for capitalizing implementation costs as they would for an arrangement that has a software license. ASU 2018-15 is effective for us on January 1, 2020 , using either a prospective or retrospective approach and with early adoption permitted. We are in the process of evaluating the effects of this guidance on our financial statements.

Acquisitions (Tables)

Acquisitions (Tables)	3 Months Ended
	Mar. 31, 2019
Business Combinations [Abstract]
Business Acquisition, Pro Forma Information	The provision for income taxes has also been adjusted for all periods, based upon the foregoing adjustments to historical results. Three Months Ended March 31, 2018 Pro forma net sales $ 209,830 Pro forma net loss $ (8,077 ) Basic net loss per share $ (0.29 ) Diluted net loss per share $ (0.29 )

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2019
Segment Reporting [Abstract]
Segment Information	The following table presents results of operations for each reportable segment. Mobile Solutions Power Solutions Life Sciences Corporate and Consolidations Total Three Months Ended March 31, 2019 Net sales $ 78,075 $ 49,657 $ 86,008 $ (484 ) (a) $ 213,256 Income (loss) from operations $ 4,107 $ 3,824 $ 3,846 $ (11,176 ) $ 601 Interest expense (13,801 ) Other (3,428 ) Loss before provision for income taxes and share of net income from joint venture $ (16,628 ) Three Months Ended March 31, 2018 Net sales $ 89,794 $ 48,682 $ 31,200 $ (528 ) (a) $ 169,148 Income (loss) from operations $ 9,785 $ 5,233 $ 4,204 $ (15,529 ) $ 3,693 Interest expense (11,996 ) Other 313 Loss before benefit for income taxes and share of net income from joint venture $ (7,990 ) _______________________________ (a) Includes elimination of intersegment transactions occurring during the ordinary course of business. Total Assets as of March 31, 2019 December 31, 2018 Mobile Solutions $ 392,100 $ 356,387 Power Solutions 311,771 297,947 Life Sciences 824,891 802,770 Corporate and Consolidations 52,231 44,466 Total $ 1,580,993 $ 1,501,570

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2019
Inventory Disclosure [Abstract]
Summary of Inventories	Inventories are comprised of the following amounts: March 31, 2019 December 31, 2018 Raw materials $ 55,286 $ 52,930 Work in process 47,372 42,578 Finished goods 26,264 27,107 Total inventories $ 128,922 $ 122,615

Goodwill (Tables)

Goodwill (Tables)	3 Months Ended
	Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in Carrying Amount of Goodwill	The following table shows changes in the carrying amount of goodwill. Mobile Solutions Power Solutions Life Sciences Total Balance as of December 31, 2018 $ — $ 94,505 $ 344,947 $ 439,452 Currency impacts — 198 519 717 Balance as of March 31, 2019 $ — $ 94,703 $ 345,466 $ 440,169

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	3 Months Ended
	Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Carrying Amount of Intangible Assets Net	The following table shows changes in the carrying amount of intangible assets, net. Mobile Solutions Power Solutions Life Sciences Total Balance as of December 31, 2018 $ 35,892 $ 95,991 $ 244,365 $ 376,248 Amortization (885 ) (2,748 ) (9,017 ) (12,650 ) Other 2 — 8 10 Balance as of March 31, 2019 $ 35,009 $ 93,243 $ 235,356 $ 363,608

Investment in Joint Venture (Ta

Investment in Joint Venture (Tables)	3 Months Ended
	Mar. 31, 2019
Equity Method Investments and Joint Ventures [Abstract]
Summarized Activity Related to Investment in Joint Venture	The following table summarizes activity related to our investment in the JV. Balance as of December 31, 2018 $ 20,364 Share of earnings 269 Foreign currency translation gain 454 Balance as of March 31, 2019 $ 21,087

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Summary of Debt	The following table presents debt balances as of March 31, 2019 , and December 31, 2018 . March 31, 2019 December 31, 2018 Senior Secured Term Loan $ 530,625 $ 532,063 Incremental Term Loan 276,000 279,000 Senior Secured Revolver 56,184 38,720 International lines of credit and other loans 10,601 9,810 Total principal 873,410 859,593 Less — current maturities of long-term debt 33,444 31,280 Principal, net of current portion 839,966 828,313 Less — unamortized debt issuance costs 13,692 16,842 Long-term debt, net of current portion $ 826,274 $ 811,471

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2019
Leases [Abstract]
Lease, Cost	The following table contains supplemental information related to leases for the three months ended March 31, 2019 : Supplemental Cash Flows Information Three Months Ended March 31, 2019 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from finance leases $ 53 Operating cash flows from operating leases 5,288 Financing cash flows from finance leases 792 Right-of-use assets obtained in exchange for new operating lease liabilities $ 2,836 As of March 31, 2019 , the weighted average remaining lease term and weighted-average discount rate for finance and operating leases was as follows: Weighted-Average Remaining Lease Term (years) Weighted-Average Discount Rate Finance leases 4.1 2.4 % Operating leases 10.5 8.5 % The following table presents components of lease expense for the three months ended March 31, 2019 : Financial Statement Line Item Three Months Ended March 31, 2019 Lease cost: Finance lease cost Amortization of right-of-use assets Depreciation and amortization $ 322 Interest expense Interest expense 53 Operating lease cost Cost of sales and selling, general and administrative expense 3,434 Short-term lease cost (1) Cost of sales and selling, general and administrative expense 107 Total lease cost $ 3,916 _______________________________ (1) Excludes expenses related to leases with a lease term of one month or less.
Assets and Liabilities, Lessee	The following table presents the lease-related assets and liabilities recorded on the balance sheet as of March 31, 2019 : Financial Statement Line Item March 31, 2019 Lease assets and liabilities: Assets Operating lease assets Operating lease right-of-use assets $ 68,458 Finance lease asset Finance lease right-of-use assets 12,886 Total lease assets $ 81,344 Liabilities Current liabilities Operating lease liabilities Current portion of operating lease liability $ 7,630 Finance lease liabilities Other current liabilities 2,401 Non-current liabilities Operating lease liabilities Operating lease liability, net of current portion 66,975 Finance lease liabilities Other non-current liabilities 6,150 Total lease liabilities $ 83,156
Lessee, Operating Lease, Liability, Maturity	The future minimum lease obligations with noncancelable terms in excess of twelve months as of March 31, 2019 , is as follows: Operating Leases Finance Leases 2019 (1) $ 10,104 $ 2,190 2020 11,979 2,033 2021 11,118 2,020 2022 10,812 1,853 2023 9,264 962 Thereafter 59,946 17 Total future minimum lease payments 113,223 9,075 Less: imputed interest 38,618 524 Total lease liabilities $ 74,605 $ 8,551 (1) For the period from April 1, 2019 to December 31, 2019 .
Finance Lease, Liability, Maturity	The future minimum lease obligations with noncancelable terms in excess of twelve months as of March 31, 2019 , is as follows: Operating Leases Finance Leases 2019 (1) $ 10,104 $ 2,190 2020 11,979 2,033 2021 11,118 2,020 2022 10,812 1,853 2023 9,264 962 Thereafter 59,946 17 Total future minimum lease payments 113,223 9,075 Less: imputed interest 38,618 524 Total lease liabilities $ 74,605 $ 8,551 (1) For the period from April 1, 2019 to December 31, 2019 .
Schedule of Future Minimum Rental Payments for Operating Leases	The following table summarizes the future minimum lease payments under operating leases with initial or non-cancelable lease terms in excess of one year prior to adoption of ASC 842 as reported in our Annual Report on Form 10-K for the year ended December 31, 2018 . Year Ending December 31, 2019 $ 13,337 2020 11,515 2021 10,557 2022 10,293 2023 8,752 Thereafter 53,945 Total minimum payments $ 108,399

Restructuring and Integration (

Restructuring and Integration (Tables)	3 Months Ended
	Mar. 31, 2019
Restructuring and Related Activities [Abstract]
Summary of Restructuring and Integration Charges and Reserve Activity	The following table summarizes restructuring and integration charges incurred for the three months ended March 31, 2019 and 2018 . Three Months Ended March 31, 2019 Mobile Power Life Corporate and Total Severance and other employee costs $ — $ — $ — $ — $ — Site closure and other associated costs (12 ) — — — (12 ) Total $ (12 ) $ — $ — $ — $ (12 ) Three Months Ended March 31, 2018 Mobile Power Life Corporate and Total Severance and other employee costs $ — $ — $ — $ 728 $ 728 Site closure and other associated costs 27 — — — 27 Total $ 27 $ — $ — $ 728 $ 755 The following table summarizes restructuring and integration reserve activity for the three months ended March 31, 2019 . Reserve Charges Non-cash Adjustments Cash Reductions Reserve Severance and other employee costs $ 1,122 $ — $ — $ (274 ) $ 848 Site closure and other associated costs 24 (12 ) — (12 ) — Total $ 1,146 $ (12 ) $ — $ (286 ) $ 848

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	3 Months Ended
	Mar. 31, 2019
Revenue from Contract with Customer [Abstract]
Summary of Revenue from Contracts with Customers	The following tables summarize sales to external customers by major source. Three Months Ended March 31, 2019 Mobile Power Life Intersegment Total United States $ 44,457 $ 41,115 $ 68,343 $ (484 ) $ 153,431 China 9,153 1,838 1,692 — 12,683 Mexico 5,378 2,709 127 — 8,214 Brazil 8,382 69 — — 8,451 Germany 1,406 16 8,885 — 10,307 Switzerland 1,359 16 3,265 — 4,640 Poland 1,913 4 6 — 1,923 Italy 1,856 63 421 — 2,340 Czech Republic 1,509 188 — — 1,697 France 44 — 1,225 — 1,269 Africa — 1,156 — — 1,156 Other 2,618 2,483 2,044 — 7,145 Total net sales $ 78,075 $ 49,657 $ 86,008 $ (484 ) $ 213,256 Three Months Ended March 31, 2018 Mobile Solutions Power Solutions Life Sciences Intersegment Sales Eliminations Total United States $ 49,655 $ 40,128 $ 30,553 $ (528 ) $ 119,808 China 11,581 1,485 126 — 13,192 Mexico 7,236 3,197 172 — 10,605 Brazil 9,885 50 — — 9,935 Poland 2,052 14 — — 2,066 Czech Republic 1,810 — — — 1,810 Italy 1,577 98 — — 1,675 Germany 1,534 7 1 — 1,542 Switzerland 1,406 — — — 1,406 Netherlands — 974 — — 974 Other 3,058 2,729 348 — 6,135 Total net sales $ 89,794 $ 48,682 $ 31,200 $ (528 ) $ 169,148
Summary of Contract Liabilities from Contracts with Customers	The following table provides information about contract liabilities from contracts with customers. Deferred Revenue Balance at January 1, 2019 $ 2,974 Balance at March 31, 2019 $ 2,890

Shared-Based Compensation (Tabl

Shared-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Components of Share-Based Compensation Expense by Type of Award	The following table lists the components of share-based compensation expense by type of award. Three Months Ended 2019 2018 Stock options $ 192 $ 205 Restricted stock 459 460 Performance share units 222 591 Share-based compensation expense $ 873 $ 1,256
Weighted Average Assumptions Relevant to Determining the Fair Value at the Dates of Grant and Stock Option Modification	The following table shows the weighted average assumptions relevant to determining the fair value of stock options granted in 2019 . 2019 Expected term 6 years Risk free interest rate 2.47 % Dividend yield 3.53 % Expected volatility 49.53 % Expected forfeiture rate 4.00 %
Reconciliation of Option Activity	The following table summarizes stock option activity for the three months ended March 31, 2019 . Number of Options (in thousands) Weighted- Average Exercise Price (per share) Weighted- Average Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at January 1, 2019 771 $ 15.17 Granted 210 7.93 Exercised — $ — Forfeited or expired (3 ) 24.41 Outstanding at March 31, 2019 978 $ 13.58 6.3 $ — (1) Exercisable at March 31, 2019 701 $ 14.27 5.0 $ — (1) _______________________________ (1) The aggregate intrinsic value is the sum of intrinsic values for each exercisable individual option grant. The intrinsic value is the amount by which the closing market price of our stock at March 31, 2019 , was greater than the exercise price of any individual option grant.
Reconciliation of Restricted Stock Option Activity	The following table summarizes the status of unvested restricted stock awards as of March 31, 2019 , and changes during the three months then ended. Nonvested Restricted Shares (in thousands) Weighted Average Grant-Date Fair Value (per share) Nonvested at January 1, 2019 146 $ 22.07 Granted 281 $ 7.93 Vested (70 ) $ 20.92 Forfeited (18 ) $ 18.98 Nonvested at March 31, 2019 339 $ 10.74
Schedule of Performance Based Awards Goals with Respect to TSR and ROIC	The following table presents the goals with respect to TSR Awards and ROIC Awards granted in 2019 . TSR Awards: Threshold Performance Target Performance Maximum Performance 2019 grants 35th Percentile 50th Percentile 75th Percentile ROIC Awards: Threshold Performance Target Performance Maximum Performance 2019 grants (1) 4.7 % 5.8 % 7.0 % (1) For the ROIC Awards granted in 2019, the denominator of the calculation is different than in prior years, and therefore the target percentages are not comparable to historical target percentages.
Schedule of Number of Awards Granted and Grant Date Fair Value of Each Award in Periods	The following table presents the number of awards granted and the grant date fair value of each award in the period presented. TSR Awards ROIC Awards Award Year Shares (in thousands) Grant Date Fair Value (per share) Shares (in thousands) Grant Date Fair Value (per share) 2019 136 $ 9.28 174 $ 7.93
Summary of Status of Unvested PSU Awards	The following table summarizes the status of unvested PSUs as of March 31, 2019 , and changes during the three months then ended. Nonvested TSR Awards Nonvested ROIC Awards Shares (in thousands) Weighted Average Grant-Date Fair Value (per share) Shares (in thousands) Weighted Average Grant-Date Fair Value (per share) Nonvested at January 1, 2019 94 $ 26.84 100 $ 24.39 Granted 136 $ 9.28 174 $ 7.93 Forfeited — $ — — $ — Nonvested at March 31, 2019 230 $ 16.47 274 $ 13.93

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	3 Months Ended
	Mar. 31, 2019
Earnings Per Share [Abstract]
Summary of Net Income (Loss) Per Share	Three Months Ended 2019 2018 Numerator: Net loss $ (18,600 ) $ (5,983 ) Denominator: Weighted average shares outstanding 41,972 27,597 Effect of dilutive stock options — — Diluted shares outstanding 41,972 27,597 Per common share net loss: Basic net loss per share $ (0.44 ) $ (0.22 ) Diluted net loss per share $ (0.44 ) $ (0.22 ) Cash dividends declared per share $ 0.07 $ 0.07

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2019
Fair Value Disclosures [Abstract]
Schedule of Notional Amounts of Outstanding Derivative Positions	The notional amount of the interest rate swap will decrease over the interest rate swap term as follows: Notional Amount February 12, 2019 - December 30, 2020 $ 700,000 December 31, 2020 - December 30, 2021 466,667 December 31, 2021 - October 19, 2022 233,333
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following shows the liabilities measured at fair value on a recurring basis for the interest rate swap as of March 31, 2019 . Fair Value Measurements as of March 31, 2019 Description Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Derivative liability - other current liabilities $ — $ 543 $ — Derivative liability - other non-current liabilities — 4,417 — Total $ — $ 4,960 $ —

Interim Financial Statements -

Interim Financial Statements - Additional Information (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2019Facility	Jan. 01, 2019USD ($)	Jan. 01, 2018USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of manufacturing facilities | Facility	51
Cumulative effect of new accounting principle of adoption		$ 18	$ 17
Accounting Standards Update 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect of new accounting principle of adoption		$ 100

Acquisitions - Additional Infor

Acquisitions - Additional Information (Detail)	Aug. 09, 2018	May 07, 2018	Feb. 22, 2018
Paragon Medical Inc
Business Acquisition [Line Items]
Acquisition percentage		100.00%
Bridgemedica, LLC
Business Acquisition [Line Items]
Acquisition percentage			100.00%
Southern California Technical Arts, Inc.
Business Acquisition [Line Items]
Acquisition percentage	100.00%

Acquisitions Pro Forma Financia

Acquisitions Pro Forma Financial Results (Details) - Paragon Medical Inc $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2018USD ($)$ / shares
Business Acquisition [Line Items]
Pro forma net sales | $	$ 209,830
Pro forma net loss | $	$ (8,077)
Basic net loss per share (in dollars per share) | $ / shares	$ (0.29)
Diluted net loss per share (in dollars per share) | $ / shares	$ (0.29)

Segment Information (Detail)

Segment Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Segment Reporting Information [Line Items]
Net sales	$ 213,256	$ 169,148
Income (loss) from operations	601	3,693
Interest expense	(13,801)	(11,996)
Other	(3,428)	313
Loss before (provision) benefit for income taxes and share of net income from joint venture	(16,628)	(7,990)
Total assets	1,580,993		$ 1,501,570
Mobile Solutions
Segment Reporting Information [Line Items]
Total assets	392,100		356,387
Power Solutions
Segment Reporting Information [Line Items]
Total assets	311,771		297,947
Life Sciences
Segment Reporting Information [Line Items]
Total assets	824,891		802,770
Corporate and Consolidations
Segment Reporting Information [Line Items]
Total assets	52,231		$ 44,466
Operating Segments | Mobile Solutions
Segment Reporting Information [Line Items]
Net sales	78,075	89,794
Income (loss) from operations	4,107	9,785
Operating Segments | Power Solutions
Segment Reporting Information [Line Items]
Net sales	49,657	48,682
Income (loss) from operations	3,824	5,233
Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Net sales	86,008	31,200
Income (loss) from operations	3,846	4,204
Corporate and Eliminations | Corporate and Consolidations
Segment Reporting Information [Line Items]
Net sales	(484)	(528)
Income (loss) from operations	$ (11,176)	$ (15,529)

Inventories - Summary of Invent

Inventories - Summary of Inventories (Detail) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 55,286	$ 52,930
Work in process	47,372	42,578
Finished goods	26,264	27,107
Total inventories	$ 128,922	$ 122,615

Goodwill - Changes in Carrying

Goodwill - Changes in Carrying Amount of Goodwill (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Goodwill [Roll Forward]
Beginning Balance	$ 439,452,000
Currency impacts	717,000
Ending Balance	440,169,000	$ 439,452,000
Mobile Solutions
Goodwill [Roll Forward]
Beginning Balance	0
Currency impacts	0
Ending Balance	0	0
Power Solutions
Goodwill [Roll Forward]
Beginning Balance	94,505,000
Currency impacts	198,000
Ending Balance	94,703,000	94,505,000
Goodwill, impairment loss	0	109,100,000
Life Sciences
Goodwill [Roll Forward]
Beginning Balance	344,947,000
Currency impacts	519,000
Ending Balance	$ 345,466,000	$ 344,947,000

Goodwill - Additional Informati

Goodwill - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Goodwill [Line Items]
Goodwill	$ 440,169,000	$ 439,452,000
Power Solutions
Goodwill [Line Items]
Goodwill, impairment loss	0	109,100,000
Goodwill	$ 94,703,000	$ 94,505,000

Intangible Assets, Net - Summar

Intangible Assets, Net - Summary of Carrying Amount of Intangible Assets by Segment (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Finite-lived Intangible Assets [Roll Forward]
Beginning Balance	$ 376,248
Amortization	(12,650)
Other	10
Ending balance	363,608
Mobile Solutions
Finite-lived Intangible Assets [Roll Forward]
Beginning Balance	35,892
Amortization	(885)
Other	2
Ending balance	35,009
Power Solutions
Finite-lived Intangible Assets [Roll Forward]
Beginning Balance	95,991
Amortization	(2,748)
Other	0
Ending balance	93,243
Life Sciences
Finite-lived Intangible Assets [Roll Forward]
Beginning Balance	244,365
Amortization	(9,017)
Other	8
Ending balance	$ 235,356

Investment in Joint Venture - A

Investment in Joint Venture - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018
Joint Venture
Schedule of Equity Method Investments [Line Items]
Impairment charge	$ 0	$ 16,600,000
Net sales			$ 100,000
Joint Venture | Maximum
Schedule of Equity Method Investments [Line Items]
Net sales	$ 100,000
Wuxi Weifu Autocam Precision Machinery Company, Ltd.
Schedule of Equity Method Investments [Line Items]
Investment in joint venture	49.00%

Investment in Joint Venture - S

Investment in Joint Venture - Summarized Activity Related to Investment in Joint Venture (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Equity Method Investments [Roll Forward]
Beginning Balance	$ 20,364
Our share of cumulative earnings	269	$ 831
Ending Balance	21,087
Joint Venture
Equity Method Investments [Roll Forward]
Beginning Balance	20,364
Our share of cumulative earnings	269
Foreign currency translation gain	454
Ending Balance	$ 21,087

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Effective tax rate from continuing operations	(13.50%)	14.70%
Change in tax rate, income tax expense (benefit)	$ 6

Debt - Summary of Debt (Detail)

Debt - Summary of Debt (Detail) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Total	$ 873,410	$ 859,593
Less current maturities of long-term debt	33,444	31,280
Principal, net of current portion	839,966	828,313
Less unamortized debt issuance costs	13,692	16,842
Long-term debt, net of current portion	826,274	811,471
Chinese
Debt Instrument [Line Items]
International lines of credit and other loans	10,601	9,810
Senior Secured Term Loan B
Debt Instrument [Line Items]
Senior debt	530,625	532,063
Incremental Term Loan
Debt Instrument [Line Items]
Senior debt	276,000	279,000
Senior Secured Revolving Facility
Debt Instrument [Line Items]
Senior debt	$ 56,184	$ 38,720

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)	Mar. 15, 2019	Mar. 31, 2019	Mar. 31, 2018	Feb. 28, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Capitalized interest costs		$ 600,000	$ 200,000
Payments of debt issuance costs		738,000	$ 0
Senior Secured Term Loan B
Debt Instrument [Line Items]
Borrowings		545,000,000
Interest rate during period			6.24%
Senior debt		$ 530,625,000			$ 532,063,000
Senior Secured Term Loan B | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Applicable margin		3.75%
Senior Secured Term Loan B | London Interbank Offered Rate (LIBOR) | Minimum
Debt Instrument [Line Items]
Interest rate		0.75%
Incremental Term Loan
Debt Instrument [Line Items]
Borrowings		$ 300,000,000
Interest rate during period		5.74%
Senior debt		$ 276,000,000			279,000,000
Incremental Term Loan | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Applicable margin		3.25%
Senior Secured Revolving Facility
Debt Instrument [Line Items]
Borrowings		$ 143,000,000
Interest rate during period		5.99%
Unused capacity, commitment fee percentage		0.50%
Principal available		$ 125,000,000
Senior debt		$ 56,184,000			$ 38,720,000
Payments of debt issuance costs	$ 800,000
Write off of deferred debt issuance cost	$ 2,700,000
Senior Secured Revolving Facility | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Applicable margin		3.50%
Interest Rate Swap
Debt Instrument [Line Items]
Derivative, notional amount				$ 700,000,000
Derivative, fixed interest rate				2.4575%

Leases - Narrative (Details)

Leases - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Jan. 01, 2019	Jan. 01, 2018
Lessee, Lease, Description [Line Items]
Cumulative effect of new accounting principle of adoption			$ 18	$ 17
Lessee, operating lease, lease not yet commenced, amount	$ 21,900
Lessee, operating lease, lease not yet commenced, term of contract	15 years
Rent expense		$ 2,100
Equipment | Minimum
Lessee, Lease, Description [Line Items]
Lessee, finance lease, term of contract	13 months
Equipment | Maximum
Lessee, Lease, Description [Line Items]
Lessee, finance lease, term of contract	5 years
Manufacturing Facility | Minimum
Lessee, Lease, Description [Line Items]
Lessee, finance lease, term of contract	13 months
Manufacturing Facility | Maximum
Lessee, Lease, Description [Line Items]
Lessee, finance lease, term of contract	25 years
Accounting Standards Update 2016-02
Lessee, Lease, Description [Line Items]
Cumulative effect of new accounting principle of adoption			100
Retained Earnings
Lessee, Lease, Description [Line Items]
Cumulative effect of new accounting principle of adoption			18	$ 17
Retained Earnings | Accounting Standards Update 2016-02
Lessee, Lease, Description [Line Items]
Cumulative effect of new accounting principle of adoption			$ 100

Leases - Finance and Operating

Leases - Finance and Operating Lease Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Finance lease cost
Amortization of right-of-use assets	$ 322
Interest expense	53
Operating lease cost	3,434
Short-term lease cost	107
Total lease cost	3,916
Assets
Operating lease right-of-use assets	68,458
Finance lease right-of-use assets	12,886
Lease, right-of-use asset	81,344
Current liabilities
Operating lease liabilities	7,630	$ 0
Finance lease liabilities	2,401
Non-current liabilities
Operating lease liabilities	66,975
Finance lease liabilities	6,150
Total lease liabilities	$ 83,156

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from finance leases	$ 53
Operating cash flows from operating leases	5,288
Financing cash flows from finance leases	792
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 2,836

Leases - Weighted Average Remai

Leases - Weighted Average Remaining Lease Term and Discount Rate (Details)	3 Months Ended
	Mar. 31, 2019
Weighted-Average Remaining Lease Term (years)
Finance leases	4 years 1 month 6 days
Operating leases	10 years 6 months 18 days
Weighted-Average Discount Rate
Finance leases	2.40%
Operating leases	8.50%

Leases - Future Minimum Lease O

Leases - Future Minimum Lease Obligations After Adoption of 842 (Details) $ in Thousands	Mar. 31, 2019USD ($)
Operating Leases
2019	$ 10,104
2020	11,979
2021	11,118
2022	10,812
2023	9,264
Thereafter	59,946
Total future minimum lease payments	113,223
Less: imputed interest	38,618
Total lease liabilities	74,605
Finance Leases
2019	2,190
2020	2,033
2021	2,020
2022	1,853
2023	962
Thereafter	17
Total future minimum lease payments	9,075
Less: imputed interest	524
Total lease liabilities	$ 8,551

Leases Leases - Future Minimum

Leases Leases - Future Minimum Lease Obligations Before Adoption of 842 (Details) $ in Thousands	Dec. 31, 2018USD ($)
Leases [Abstract]
2019	$ 13,337
2020	11,515
2021	10,557
2022	10,293
2023	8,752
Thereafter	53,945
Total minimum payments	$ 108,399

Restructuring and Integration -

Restructuring and Integration - Summary of Restructuring and Integration Charges and Reserve Activity (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Restructuring Cost and Reserve [Line Items]
Severance and other employee costs	$ 0	$ 728
Other	(12)	27
Restructuring Reserve [Roll Forward]
Reserve beginning balance	1,146
Charges	(12)	755
Non-cash Adjustments	0
Cash Reductions	(286)
Reserve ending balance	848
Severance and Other Employee Costs
Restructuring Reserve [Roll Forward]
Reserve beginning balance	1,122
Charges	0
Non-cash Adjustments	0
Cash Reductions	(274)
Reserve ending balance	848
Site Closure and Other Associated Costs
Restructuring Reserve [Roll Forward]
Reserve beginning balance	24
Charges	(12)
Non-cash Adjustments	0
Cash Reductions	(12)
Reserve ending balance	0
Operating Segments | Mobile Solutions
Restructuring Cost and Reserve [Line Items]
Severance and other employee costs	0	0
Other	(12)	27
Restructuring Reserve [Roll Forward]
Charges	(12)	27
Operating Segments | Power Solutions
Restructuring Cost and Reserve [Line Items]
Severance and other employee costs	0	0
Other	0	0
Restructuring Reserve [Roll Forward]
Charges	0	0
Operating Segments | Life Sciences
Restructuring Cost and Reserve [Line Items]
Severance and other employee costs	0	0
Other	0	0
Restructuring Reserve [Roll Forward]
Charges	0	0
Corporate and Eliminations | Corporate and Consolidations
Restructuring Cost and Reserve [Line Items]
Severance and other employee costs	0	728
Other	0	0
Restructuring Reserve [Roll Forward]
Charges	$ 0	$ 728

Restructuring and Integration_2

Restructuring and Integration - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2019USD ($)
Restructuring and Related Activities [Abstract]
Pay period for accrued restructuring and integration costs	1 year 10 months 25 days
Restructuring and related cost, expected cost remaining	$ 0.5

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	Mar. 31, 2019USD ($)
Contingencies And Commitments [Line Items]
Amount accrued for estimation of loss	$ 0
Minimum
Contingencies And Commitments [Line Items]
Possible loss estimated	0
Maximum
Contingencies And Commitments [Line Items]
Possible loss estimated	$ 6,000,000

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Summary of Revenue from Contracts with Customers (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenue, Major Customer [Line Items]
Net sales	$ 213,256	$ 169,148
Intersegment Sales Eliminations
Revenue, Major Customer [Line Items]
Net sales	(484)	(528)
United States
Revenue, Major Customer [Line Items]
Net sales	153,431	119,808
United States | Intersegment Sales Eliminations
Revenue, Major Customer [Line Items]
Net sales	(484)	(528)
Chinese
Revenue, Major Customer [Line Items]
Net sales	12,683	13,192
Chinese | Intersegment Sales Eliminations
Revenue, Major Customer [Line Items]
Net sales	0	0
Mexico
Revenue, Major Customer [Line Items]
Net sales	8,214	10,605
Mexico | Intersegment Sales Eliminations
Revenue, Major Customer [Line Items]
Net sales	0	0
Brazil
Revenue, Major Customer [Line Items]
Net sales	8,451	9,935
Brazil | Intersegment Sales Eliminations
Revenue, Major Customer [Line Items]
Net sales	0	0
Germany
Revenue, Major Customer [Line Items]
Net sales	10,307	1,542
Germany | Intersegment Sales Eliminations
Revenue, Major Customer [Line Items]
Net sales	0	0
Switzerland
Revenue, Major Customer [Line Items]
Net sales	4,640	1,406
Switzerland | Intersegment Sales Eliminations
Revenue, Major Customer [Line Items]
Net sales	0	0
Poland
Revenue, Major Customer [Line Items]
Net sales	1,923	2,066
Poland | Intersegment Sales Eliminations
Revenue, Major Customer [Line Items]
Net sales	0	0
Italy
Revenue, Major Customer [Line Items]
Net sales	2,340	1,675
Italy | Intersegment Sales Eliminations
Revenue, Major Customer [Line Items]
Net sales	0	0
Czech Republic
Revenue, Major Customer [Line Items]
Net sales	1,697	1,810
Czech Republic | Intersegment Sales Eliminations
Revenue, Major Customer [Line Items]
Net sales	0	0
FRANCE
Revenue, Major Customer [Line Items]
Net sales	1,269
FRANCE | Intersegment Sales Eliminations
Revenue, Major Customer [Line Items]
Net sales	0
Africa
Revenue, Major Customer [Line Items]
Net sales	1,156
Africa | Intersegment Sales Eliminations
Revenue, Major Customer [Line Items]
Net sales	0
Netherlands
Revenue, Major Customer [Line Items]
Net sales		974
Netherlands | Intersegment Sales Eliminations
Revenue, Major Customer [Line Items]
Net sales		0
Other Country
Revenue, Major Customer [Line Items]
Net sales	7,145	6,135
Other Country | Intersegment Sales Eliminations
Revenue, Major Customer [Line Items]
Net sales	0	0
Mobile Solutions | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	78,075	89,794
Mobile Solutions | United States | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	44,457	49,655
Mobile Solutions | Chinese | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	9,153	11,581
Mobile Solutions | Mexico | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	5,378	7,236
Mobile Solutions | Brazil | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	8,382	9,885
Mobile Solutions | Germany | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	1,406	1,534
Mobile Solutions | Switzerland | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	1,359	1,406
Mobile Solutions | Poland | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	1,913	2,052
Mobile Solutions | Italy | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	1,856	1,577
Mobile Solutions | Czech Republic | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	1,509	1,810
Mobile Solutions | FRANCE | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	44
Mobile Solutions | Africa | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	0
Mobile Solutions | Netherlands | Operating Segments
Revenue, Major Customer [Line Items]
Net sales		0
Mobile Solutions | Other Country | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	2,618	3,058
Power Solutions | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	49,657	48,682
Power Solutions | United States | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	41,115	40,128
Power Solutions | Chinese | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	1,838	1,485
Power Solutions | Mexico | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	2,709	3,197
Power Solutions | Brazil | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	69	50
Power Solutions | Germany | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	16	7
Power Solutions | Switzerland | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	16	0
Power Solutions | Poland | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	4	14
Power Solutions | Italy | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	63	98
Power Solutions | Czech Republic | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	188	0
Power Solutions | FRANCE | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	0
Power Solutions | Africa | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	1,156
Power Solutions | Netherlands | Operating Segments
Revenue, Major Customer [Line Items]
Net sales		974
Power Solutions | Other Country | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	2,483	2,729
Life Sciences | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	86,008	31,200
Life Sciences | United States | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	68,343	30,553
Life Sciences | Chinese | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	1,692	126
Life Sciences | Mexico | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	127	172
Life Sciences | Brazil | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	0	0
Life Sciences | Germany | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	8,885	1
Life Sciences | Switzerland | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	3,265	0
Life Sciences | Poland | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	6	0
Life Sciences | Italy | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	421	0
Life Sciences | Czech Republic | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	0	0
Life Sciences | FRANCE | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	1,225
Life Sciences | Africa | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	0
Life Sciences | Netherlands | Operating Segments
Revenue, Major Customer [Line Items]
Net sales		0
Life Sciences | Other Country | Operating Segments
Revenue, Major Customer [Line Items]
Net sales	$ 2,044	$ 348

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Summary of Contract Liabilities from Contracts with Customers (Detail) $ in Thousands	Mar. 31, 2019USD ($)
Contract with Customer, Liability [Abstract]
Deferred revenue, beginning balance	$ 2,974
Deferred revenue, ending balance	$ 2,890

Revenue from Contracts with C_5

Revenue from Contracts with Customers Additional Information (Details) $ in Millions	3 Months Ended
	Mar. 31, 2019USD ($)
Revenue, Major Customer [Line Items]
Amounts included in deferred revenue for performance obligations satisfied or partially satisfied	$ 0.6
Major Customer
Revenue, Major Customer [Line Items]
Revenues	$ 23.3
Major Customer | Customer Concentration Risk | Sales Revenue, Net
Revenue, Major Customer [Line Items]
Concentration risk, percentage	10.90%

Shared-Based Compensation - Com

Shared-Based Compensation - Components of Share-Based Compensation Expense by Type of Award (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	$ 873	$ 1,256
Stock Option Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	192	205
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	459	460
Performance Based Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	$ 222	$ 591

Shared-Based Compensation - Add

Shared-Based Compensation - Additional Information (Detail) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2019USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted (in shares)	210,400
Weighted average grant date fair value of the options granted (in USD per share) | $ / shares	$ 2.77
Total grant-date fair value of restricted stock | $	$ 1.5
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock units issued (in shares)	281,065
Fair value assumptions, exercise price (in USD per share) | $ / shares	$ 7.93
TSR Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock units issued (in shares)	136,000
Percentage of shares issuable based on threshold performance	50.00%
Percentage of shares issuable based on maximum performance	150.00%
ROIC Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock units issued (in shares)	174,000
Percentage of shares issuable based on threshold performance	35.00%
Percentage of shares issuable based on target performance	100.00%
Percentage of shares issuable based on maximum performance	150.00%
Officers and Key Employees | Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock awards granted vesting period	3 years
Non-executive Directors | Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock awards granted vesting period	1 year

Shared-Based Compensation - Wei

Shared-Based Compensation - Weighted Average Assumptions Relevant to Determining the Fair Value at the Dates of Grant and Stock Option Modification (Detail) - Stock Option Awards	3 Months Ended
	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	6 years
Risk free interest rate	2.47%
Dividend yield	3.53%
Expected volatility	49.53%
Expected forfeiture rate	4.00%

Shared-Based Compensation - Rec

Shared-Based Compensation - Reconciliation of Option Activity (Detail) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)$ / sharesshares
Number of Options (in thousands)
Beginning balance (in shares) | shares	771,000
Granted (in shares) | shares	210,400
Exercised (in shares) | shares	0
Forfeitures (in shares) | shares	(3,000)
Ending balance (in shares) | shares	978,000
Options exercisable (in shares) | shares	701,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Beginning balance (in USD per share) | $ / shares	$ 15.17
Granted (in USD per share) | $ / shares	7.93
Exercised (in USD per share) | $ / shares
Forfeitures (in USD per share) | $ / shares	24.41
Ending balance (in USD per share) | $ / shares	13.58
Options exercisable (in USD per share) | $ / shares	$ 14.27
Weighted-average remaining contractual term, outstanding	6 years 3 months 14 days
Weighted- average remaining contractual term, options exercisable	5 years
Aggregate intrinsic value, exercised | $	$ 0
Aggregate intrinsic value, outstanding | $	0
Aggregate intrinsic value, options exercisable | $	$ 0

Shared-Based Compensation - R_2

Shared-Based Compensation - Reconciliation of Restricted Stock Option Activity (Detail)	3 Months Ended
	Mar. 31, 2019$ / sharesshares
Restricted Stock
Nonvested Shares (in thousands)
Nonvested restricted shares, beginning balance (in shares) | shares	146,000
Nonvested restricted shares, granted (in shares) | shares	281,065
Nonvested restricted shares, vested (in shares) | shares	(70,000)
Nonvested restricted shares, forfeited (in shares) | shares	(18,000)
Nonvested restricted shares, ending balance (in shares) | shares	339,000
Weighted average grant-date fair value, beginning balance (in USD per share) | $ / shares	$ 22.07
Weighted average grant-date fair value, granted (in USD per share) | $ / shares	7.93
Weighted average grant-date fair value, vested (in USD per share) | $ / shares	20.92
Weighted average grant-date fair value, forfeited (in USD per share) | $ / shares	18.98
Weighted average grant-date fair value, ending balance (in USD per share) | $ / shares	$ 10.74
TSR Awards
Nonvested Shares (in thousands)
Nonvested restricted shares, beginning balance (in shares) | shares	94,000
Nonvested restricted shares, granted (in shares) | shares	136,000
Nonvested restricted shares, forfeited (in shares) | shares	0
Nonvested restricted shares, ending balance (in shares) | shares	230,000
Weighted average grant-date fair value, beginning balance (in USD per share) | $ / shares	$ 26.84
Weighted average grant-date fair value, granted (in USD per share) | $ / shares	9.28
Weighted average grant-date fair value, forfeited (in USD per share) | $ / shares	0
Weighted average grant-date fair value, ending balance (in USD per share) | $ / shares	$ 16.47
ROIC Awards
Nonvested Shares (in thousands)
Nonvested restricted shares, beginning balance (in shares) | shares	100,000
Nonvested restricted shares, granted (in shares) | shares	174,000
Nonvested restricted shares, forfeited (in shares) | shares	0
Nonvested restricted shares, ending balance (in shares) | shares	274,000
Weighted average grant-date fair value, beginning balance (in USD per share) | $ / shares	$ 24.39
Weighted average grant-date fair value, granted (in USD per share) | $ / shares	7.93
Weighted average grant-date fair value, forfeited (in USD per share) | $ / shares	0
Weighted average grant-date fair value, ending balance (in USD per share) | $ / shares	$ 13.93

Shared-Based Compensation - Sch

Shared-Based Compensation - Schedule of Performance Based Awards Goals with Respect to TSR and ROIC (Detail)	3 Months Ended
	Mar. 31, 2019
TSR Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Threshold performance, percentage	35.00%
Target performance, percentage	50.00%
Maximum performance, percentage	75.00%
ROIC Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Threshold performance, percentage	4.70%
Target performance, percentage	5.80%
Maximum performance, percentage	7.00%

Shared-Based Compensation - Sum

Shared-Based Compensation - Summary of Number of Awards Granted and Grand Date Fair Value (Detail) shares in Thousands	3 Months Ended
	Mar. 31, 2019$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Date Fair Value (in USD per share)	$ 7.93
TSR Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards granted in fair values (in shares) | shares	136
Grant Date Fair Value (in USD per share)	$ 9.28
ROIC Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards granted in fair values (in shares) | shares	174
Grant Date Fair Value (in USD per share)	$ 7.93

Net Income (Loss) Per Share - S

Net Income (Loss) Per Share - Summary of Net Income (Loss) Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Earnings Per Share [Abstract]
Net loss	$ (18,600)	$ (5,983)
Weighted average shares outstanding (in shares)	41,972	27,597
Effect of dilutive stock options (in shares)	0	0
Diluted shares outstanding (in shares)	41,972	27,597
Basic - net loss per share (in dollars per share)	$ (0.44)	$ (0.22)
Diluted - net loss per share (in dollars per share)	(0.44)	(0.22)
Cash dividends declared per share (in dollars per share)	$ 0.07	$ 0.07

Net Income (Loss) Per Share - A

Net Income (Loss) Per Share - Additional Information (Detail) - shares shares in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Stock Option Awards
Net Income Per Share [Line Items]
Anti-dilutive securities excluded from the calculation of diluted earnings per share from continuing operation	0.7	0.5

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Feb. 28, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed-rate debt, outstanding	$ 10,600,000
Change in fair value of interest rate swap, net of tax	(3,856,000)	$ 0
Interest Rate Swap
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative, notional amount			$ 700,000,000
Derivative, fixed interest rate			2.4575%
Change in fair value of interest rate swap, net of tax	$ (3,900,000)

Fair Value Measurements - Notio

Fair Value Measurements - Notional Amounts of the Interest Rate Swap (Details)	Mar. 31, 2019USD ($)
February 12, 2019 - December 30, 2020
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative, notional amount	$ 700,000
December 31, 2020 - December 30, 2021
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative, notional amount	466,667
December 31, 2021 - October 19, 2022
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative, notional amount	$ 233,333

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - Fair Value, Measurements, Recurring $ in Thousands	Mar. 31, 2019USD ($)
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative liability - other current liabilities	$ 0
Derivative liability - other non-current liabilities	0
Total	0
Significant Other Observable Inputs (Level 2)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative liability - other current liabilities	543
Derivative liability - other non-current liabilities	4,417
Total	4,960
Significant Unobservable Inputs (Level 3)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative liability - other current liabilities	0
Derivative liability - other non-current liabilities	0
Total	$ 0